The Food and Drug Administration confirmed a shortage of Adderall and generic versions of the drug, saying patients could use alternative treatments until supply issues are resolved.
The FDA this week said what patients, manufacturers and retailers have been signaling for months: that patients with attention-deficit hyperactivity disorder are having trouble obtaining the medications that can help them focus.
